IPA analysis of the integrated data indicated that volasertib modulates glioma relevant pathways including glucocorticoid receptor [47], AMPK [48], ATM [36] and ERK/MAPK [29] (Figure 4H). This evidence concerns the gene NR3C1 and central nervous system cancer.